<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="365035">
  <stage>Registered</stage>
  <submitdate>21/09/2013</submitdate>
  <approvaldate>25/09/2013</approvaldate>
  <actrnumber>ACTRN12613001070729</actrnumber>
  <trial_identification>
    <studytitle>The effect of Mitomycin C in children with long caustic esophageal strictures</studytitle>
    <scientifictitle>The effect of topical Mitomycin C application on resolution of dysphagia in children with long segment caustic esophageal strictures</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>dysphagia in children with caustic esophageal stricture</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>topical mitomycin c is applied on the site of esophageal stricture after endoscopic dilatation.
mitomycin c is prepared to have a concentration of 0.5 mg/ml to be applied on the stricture site for 5 minutes. this application is done once for 5 min at the  session of endoscopic dilatation session.
endoscopic dilatation is done using flexible endoscopy and wire guided malleable dilator, we perform a dilatation session every 2 weeks in first 3 months then monthly for the next 9 months.
endoscopic dilatation is done regularly at this scheduled sessions, and mitomycin application is done every other session . this applied for  2 to 6 times according to the response of each patient and the improvement of his dysphagia ( if he get free after 2 application, no more sessions is needed)(and if he didn't get improved , we continue to 6 application times). </interventions>
    <comparator>no control group</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Drugs</interventioncode>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>percentage of patients that get resolved from dysphagia
(no. of patients that got resolved from dysphagia/total no of the patients x 100)

dysphagia is assessed according to dysphagia scoring system graded from 0 to 4 (where 0 represent no dysphagia, 1 = dysphagia to solids, 2 = dysphagia to semisolids, 3 = dysphagia to fluids, 4 = absolute dysphagia even to saliva)</outcome>
      <timepoint>1 year after last dilatation session</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>number of dilatation sessions needed to get free from dysphagia</outcome>
      <timepoint>1 year after last dilatation session</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>patients with long segment (&gt; 3 cm) caustic esophageal stricture</inclusivecriteria>
    <inclusiveminage>1</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>6</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>short strictures (&lt; 3 cm in length) 
patients underwent previous esophageal surgery 
undilatable strictures 
patients known to have a hypersensitivity or contraindication for mitomycin c</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2 / Phase 3</phase>
    <anticipatedstartdate>1/01/2009</anticipatedstartdate>
    <actualstartdate>16/01/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate>10/06/2011</actualenddate>
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Egypt</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Pediatric Surgery Department, Ain Shams University</primarysponsorname>
    <primarysponsoraddress>56 Ramsis st., El-Abbasia
postal code: 11566</primarysponsoraddress>
    <primarysponsorcountry>Egypt</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Pediatric Surgery Department, Ain Shams University</fundingname>
      <fundingaddress>56 Ramsis st., El-Abbasia
postal code: 11566</fundingaddress>
      <fundingcountry>Egypt</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>El-Demerdash hospital</sponsorname>
      <sponsoraddress>56 Ramsis st., El-Abbasia
postal code: 11566</sponsoraddress>
      <sponsorcountry>Egypt</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>long caustic esophageal strictures are usually difficult to be managed and have poor response to frequent endoscopic dilatation. Therefore, esophageal replacement is eventually indicated for these children. Topical mitomycin C (MMC) application has been recently used to improve the results of endoscopic dilatation for localized esophageal strictures. Our aim is to assess the role of MMC application in management of long segment caustic esophageal strictures.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>pediatric surgery departmnet, Ain Shams University</ethicname>
      <ethicaddress>56 Ramsis st., EL-Abbasia
postal code: 11566</ethicaddress>
      <ethicapprovaldate>1/01/2009</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Egypt</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Khaled Mohamed El-Asmar</name>
      <address>14 mostafa Sdek El-Rafeay, Heliopolis
postal code: 11361
Ain Shams University hospitals</address>
      <phone>+2 01001222624</phone>
      <fax />
      <email>khaled80@hotmail.com</email>
      <country>Egypt</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Khaled Mohamed El-Asmar</name>
      <address>14 mostafa Sdek El-Rafeay, Heliopolis
postal code: 11361
Ain Shams University hospitals</address>
      <phone>+2 01001222624</phone>
      <fax />
      <email>khaled80@hotmail.com</email>
      <country>Egypt</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Khaled Mohamed El-Asmar</name>
      <address>14 mostafa Sdek El-Rafeay, Heliopolis
postal code: 11361
Ain Shams University hospitals</address>
      <phone>+2 01001222624</phone>
      <fax />
      <email>khaled80@hotmail.com</email>
      <country>Egypt</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Khaled Mohamed El-Asmar</name>
      <address>14 mostafa Sdek El-Rafeay, Heliopolis</address>
      <phone>+2 01001222624</phone>
      <fax />
      <email>khaled80@hotmail.com</email>
      <country>Egypt</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>